Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACRS NASDAQ:AMLX NASDAQ:IOVA NASDAQ:PHAT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$1.95-1.0%$1.73$1.05▼$5.17$213.41M0.27779,402 shs2.24 million shsAMLXAmylyx Pharmaceuticals$11.65-1.6%$8.64$2.48▼$12.25$1.06B-0.441.76 million shs2.15 million shsIOVAIovance Biotherapeutics$2.27-6.2%$2.44$1.64▼$12.51$875.69M0.8210.70 million shs8.51 million shsPHATPhathom Pharmaceuticals$11.84-1.8%$10.15$2.21▼$19.71$855.59M0.441.08 million shs775,502 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics-1.02%-7.14%+14.71%+32.65%+65.25%AMLXAmylyx Pharmaceuticals-1.60%+14.22%+40.36%+111.05%+353.31%IOVAIovance Biotherapeutics-6.20%-8.84%-7.54%+1.34%-75.72%PHATPhathom Pharmaceuticals-1.82%-4.05%+13.15%+11.28%-36.68%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$1.95-1.0%$1.73$1.05▼$5.17$213.41M0.27779,402 shs2.24 million shsAMLXAmylyx Pharmaceuticals$11.65-1.6%$8.64$2.48▼$12.25$1.06B-0.441.76 million shs2.15 million shsIOVAIovance Biotherapeutics$2.27-6.2%$2.44$1.64▼$12.51$875.69M0.8210.70 million shs8.51 million shsPHATPhathom Pharmaceuticals$11.84-1.8%$10.15$2.21▼$19.71$855.59M0.441.08 million shs775,502 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics-1.02%-7.14%+14.71%+32.65%+65.25%AMLXAmylyx Pharmaceuticals-1.60%+14.22%+40.36%+111.05%+353.31%IOVAIovance Biotherapeutics-6.20%-8.84%-7.54%+1.34%-75.72%PHATPhathom Pharmaceuticals-1.82%-4.05%+13.15%+11.28%-36.68%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRSAclaris Therapeutics 3.11Buy$8.71346.89% UpsideAMLXAmylyx Pharmaceuticals 3.00Buy$12.255.15% UpsideIOVAIovance Biotherapeutics 2.36Hold$11.90424.23% UpsidePHATPhathom Pharmaceuticals 3.00Buy$17.5047.80% UpsideCurrent Analyst Ratings BreakdownLatest ACRS, AMLX, IOVA, and PHAT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/28/2025AMLXAmylyx PharmaceuticalsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$10.00 ➝ $14.008/19/2025IOVAIovance BiotherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.008/12/2025IOVAIovance BiotherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold8/8/2025IOVAIovance BiotherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$18.00 ➝ $14.008/8/2025IOVAIovance BiotherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$25.00 ➝ $20.007/23/2025IOVAIovance BiotherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.007/15/2025IOVAIovance BiotherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeNeutral ➝ Sell7/10/2025ACRSAclaris TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$6.007/10/2025AMLXAmylyx PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy$10.006/25/2025ACRSAclaris TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$16.006/24/2025AMLXAmylyx PharmaceuticalsJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageHold(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRSAclaris Therapeutics$18.72M11.28N/AN/A$1.44 per share1.35AMLXAmylyx Pharmaceuticals$87.37M11.89N/AN/A$2.40 per share4.85IOVAIovance Biotherapeutics$164.07M5.01N/AN/A$2.33 per share0.97PHATPhathom Pharmaceuticals$114.04M7.37N/AN/A($3.71) per share-3.19Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRSAclaris Therapeutics-$132.07M-$1.37N/AN/AN/A-802.03%-34.01%-24.18%11/5/2025 (Estimated)AMLXAmylyx Pharmaceuticals-$301.74M-$2.50N/AN/AN/AN/A-82.48%-70.15%11/6/2025 (Estimated)IOVAIovance Biotherapeutics-$372.18M-$1.23N/AN/AN/A-161.44%-52.87%-41.31%11/6/2025 (Estimated)PHATPhathom Pharmaceuticals-$334.33M-$4.73N/AN/AN/A-289.51%N/A-90.40%11/6/2025 (Estimated)Latest ACRS, AMLX, IOVA, and PHAT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025ACRSAclaris Therapeutics-$0.13-$0.13N/A-$0.13$1.34 million$1.78 million8/7/2025Q2 2025AMLXAmylyx Pharmaceuticals-$0.44-$0.46-$0.02-$0.46N/AN/A8/7/2025Q2 2025IOVAIovance Biotherapeutics-$0.29-$0.33-$0.04-$0.33$67.14 million$59.95 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACRSAclaris TherapeuticsN/AN/AN/AN/AN/AAMLXAmylyx PharmaceuticalsN/AN/AN/AN/AN/AIOVAIovance BiotherapeuticsN/AN/AN/AN/AN/APHATPhathom PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRSAclaris TherapeuticsN/A3.883.88AMLXAmylyx PharmaceuticalsN/A8.728.72IOVAIovance BiotherapeuticsN/A3.272.89PHATPhathom PharmaceuticalsN/A2.382.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRSAclaris Therapeutics98.34%AMLXAmylyx Pharmaceuticals95.84%IOVAIovance Biotherapeutics77.03%PHATPhathom Pharmaceuticals99.01%Insider OwnershipCompanyInsider OwnershipACRSAclaris Therapeutics5.60%AMLXAmylyx Pharmaceuticals12.30%IOVAIovance Biotherapeutics10.30%PHATPhathom Pharmaceuticals23.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACRSAclaris Therapeutics100108.33 million102.27 millionOptionableAMLXAmylyx Pharmaceuticals20089.17 million78.20 millionOptionableIOVAIovance Biotherapeutics500361.85 million324.58 millionOptionablePHATPhathom Pharmaceuticals11070.94 million54.63 millionOptionableACRS, AMLX, IOVA, and PHAT HeadlinesRecent News About These Companies596,108 Shares in Phathom Pharmaceuticals, Inc. $PHAT Bought by Jacobs Levy Equity Management Inc.September 12 at 3:55 AM | marketbeat.comWall Street Analysts See a 66.13% Upside in Phathom Pharmaceuticals (PHAT): Can the Stock Really Move This High?September 8, 2025 | zacks.comPhathom Pharmaceuticals: The IP Question Is Answered, But Can Management Deliver (Rating Upgrade)September 8, 2025 | seekingalpha.comNuveen LLC Makes New $637,000 Investment in Phathom Pharmaceuticals, Inc. $PHATSeptember 6, 2025 | marketbeat.com683 Capital Management LLC Grows Holdings in Phathom Pharmaceuticals, Inc. $PHATSeptember 4, 2025 | marketbeat.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives $17.50 Consensus Price Target from AnalystsSeptember 4, 2025 | americanbankingnews.comRussell Investments Group Ltd. Purchases Shares of 41,799 Phathom Pharmaceuticals, Inc. $PHATSeptember 3, 2025 | marketbeat.comPropel Bio Management LLC Has $7.12 Million Stock Holdings in Phathom Pharmaceuticals, Inc. $PHATSeptember 2, 2025 | marketbeat.comWellington Management Group LLP Raises Stock Holdings in Phathom Pharmaceuticals, Inc. $PHATSeptember 2, 2025 | marketbeat.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives Consensus Recommendation of "Buy" from AnalystsSeptember 2, 2025 | marketbeat.comPhathom Pharmaceuticals to Participate in Upcoming Investor ConferencesAugust 25, 2025 | globenewswire.comWall Street Analysts Think Phathom Pharmaceuticals (PHAT) Could Surge 87.21%: Read This Before Placing a BetAugust 22, 2025 | zacks.comPhathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder’s Ownership Following Administrative Change to 13D FilingAugust 20, 2025 | taiwannews.com.twTPhathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder's Ownership Following Administrative Change to 13D FilingAugust 20, 2025 | globenewswire.comPhathom Pharmaceuticals (NASDAQ:PHAT) Shares Up 4.4% - Still a Buy?August 16, 2025 | marketbeat.comPhathom Pharmaceuticals (PHAT) Gets a Buy from H.C. WainwrightAugust 14, 2025 | theglobeandmail.comPhathom Pharmaceuticals (PHAT) Gets a Buy from GuggenheimAugust 14, 2025 | theglobeandmail.comPhathom Pharmaceuticals’ Earnings Call Highlights Growth and ChallengesAugust 13, 2025 | msn.comPhathom Pharmaceuticals Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS In LineAugust 9, 2025 | finance.yahoo.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q2 2025 Earnings Call TranscriptAugust 9, 2025 | insidermonkey.comPhathom (PHAT) Q2 Revenue Jumps 441%August 8, 2025 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeACRS, AMLX, IOVA, and PHAT Company DescriptionsAclaris Therapeutics NASDAQ:ACRS$1.95 -0.02 (-1.02%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.96 +0.01 (+0.26%) As of 09/12/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.Amylyx Pharmaceuticals NASDAQ:AMLX$11.65 -0.19 (-1.60%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$11.66 +0.00 (+0.04%) As of 09/12/2025 07:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.Iovance Biotherapeutics NASDAQ:IOVA$2.27 -0.15 (-6.20%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$2.32 +0.05 (+2.20%) As of 09/12/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.Phathom Pharmaceuticals NASDAQ:PHAT$11.84 -0.22 (-1.82%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$11.84 0.00 (0.00%) As of 09/12/2025 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
